ATO, a GLI antagonist, blocks GLI protein function (111) and when combined with the SMO inhibitor, itraconazole, it effectively overcomes the resistance to SMO inhibition seen in models of medulloblastoma and BCC (112). The gene discussed is GLI1; the disease is skin basal cell carcinoma.